The role of afatinib in patients with EGFR NSCLC

Bookmark and Share
Published: 18 Apr 2019
Views: 978
Rating:
Save
Dr Antonio Passaro - European Institute of Oncology, Milan, Italy

Dr Antonio Passaro speaks to ecancer at the European Lung Cancer Congress 2019.

He outlines the Phase III trial which evaluates the role of afatinib in patients with EGFR NSCLC.

Dr Passaro describes the data so far, and also some of the future prospects for the research, including a comparison of clinical trail and clinical practise data.

He finishes by outlining the toxicity profile of the combination.